Hepatology (Baltimore, Md.)
Hepatology (Baltimore, Md.)
Audio Summaries
Every issue of Hepatology (Baltimore, Md.) moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
Hepatology (Baltimore, Md.) covers research in these specialties.
Recent summaries
The latest articles summarized from Hepatology (Baltimore, Md.).
Macrophage-neutrophil crosstalk via the Selplg-Sell-YAP axis drives NETosis and MASH-associated liver fibrosis
Jun 11, 2026
The authors investigate the immune mechanisms underlying the transition from inflammation to fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), specifically focusing on the crosstalk between macrophages and neutrophils. They identify the Selplg-Sell-YAP signaling axis as a key driver of neutrophil extracellular trap (NET) formation, which subsequently activates hepatic stellate cells and promotes fibrosis. The study suggests that targeting this axis could offer therapeutic potential for MASH-associated liver fibrosis.
Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial
Jun 10, 2026
The study aimed to determine the lowest effective dose of vitamin E that would lead to the greatest reduction in serum alanine aminotransferase (ALT) levels in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and elevated aminotransferases. Results indicated that a daily dose of 200 IU of vitamin E was as effective as higher doses in reducing ALT levels and normalizing them in a greater proportion of patients, with no significant safety concerns observed.
HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression
Jun 9, 2026
The authors aimed to determine whether HBsAg seroclearance offers additional clinical benefits over complete viral suppression in patients with chronic hepatitis B and cirrhosis. Their findings indicate that while HBsAg seroclearance significantly reduces the risk of hepatocellular carcinoma (HCC), it does not affect the risk of hepatic decompensation compared to patients with only complete viral suppression.